Is Maribavir registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Maribavir, including LIVTENCITY (200 mg, Film-coated tablet, SAR 52742.45).

Is Maribavir approved by the US FDA?

Drugs@FDA lists 1 application product line for Maribavir, including LIVTENCITY (Prescription).

Is Maribavir authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Maribavir: Livtencity.

Are there safety signals or safety updates for Maribavir?

US FDA: 1 entry (latest 2025-11-21).

Active substance

Maribavir

SFDA 1
US FDA 1
EMA 1
Health Canada 1
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
LIVTENCITY	200 mg	Film-coated tablet · Oral use	56 Bottle	SAR 52742.45	NCE · Prescription	Takeda Pharmaceuticals International AG	Valid

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
LIVTENCITY	200MG	tablet · oral	TAKEDA PHARMS USA	Prescription	23 Nov 2021

EMA European Union — centrally authorised medicines

Livtencity Takeda Pharmaceuticals International AG Ireland Branch · Authorised · authorised 9 Nov 2022 · ATC J05AX10

Therapeutic indication (EMA)

LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
LIVTENCITY	02530740	200 MG	TABLET · ORAL	TAKEDA CANADA INC

Safety signals and safety-related labeling changes

US FDA 21 Nov 2025 LIVTENCITY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for maribavir →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.